NCT03751488View on ClinicalTrials.gov

A Study to Determine Pharmacokinetic Characteristics of LY03010 Versus INVEGA SUSTENNA® in Schizophrenia Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

December 12, 2018

Primary Completion Date

July 24, 2019

Study Completion Date

July 24, 2019

Conditions
Schizo Affective DisorderSchizophreniaSchizoaffective Disorder
Interventions
DRUG

LY03010

Single Dose of LY03010 at 351 mg or 156 mg or 117mg

DRUG

Invega Sustenna 156 MG in 1 ML Prefilled Syringe

Single Dose at 156mg

Trial Locations (2)

92845

Collaborative Neuroscience Network LLC, Garden Grove

08009

Hassman Research Institute, Berlin

All Listed Sponsors
lead

Luye Pharma Group Ltd.

INDUSTRY

NCT03751488 - A Study to Determine Pharmacokinetic Characteristics of LY03010 Versus INVEGA SUSTENNA® in Schizophrenia Patients | Biotech Hunter | Biotech Hunter